Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · IEX Real-Time Price · USD
26.56
+0.02 (0.08%)
At close: Jul 19, 2024, 4:00 PM
26.45
-0.11 (-0.41%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Marino Garcia M.B.A. |
Contact Details
Address: 300 Technology Square, 8th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | 857-201-2700 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer, Secretary and Director |
| Ryan Savitz | Chief Financial Officer and Chief Business Officer and Treasurer |
| Edward G. Carr | Chief Accounting Officer |
| Judson Taylor | Head of Technical Operations |
| Dr. Jeffrey Stavenhagen Ph.D. | Chief Scientific Officer |
| Jennifer Davis Ruff | Vice President and Head of Investor Relations and Corporate Affairs. |
| Adam M. Veness Esq. | General Counsel |
| Kristina Maximenko | Chief People Officer |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
| Rashieda Gluck | Head of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2024 | 8-K | Current Report |
| May 28, 2024 | 424B3 | Prospectus |
| May 28, 2024 | 8-K | Current Report |
| May 9, 2024 | 424B3 | Prospectus |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |